» Articles » PMID: 39744193

External Validation of EncephalApp Stroop Test to Screen Minimal Hepatic Encephalopathy Patients with Nonalcoholic Cirrhosis

Overview
Journal World J Hepatol
Specialty Gastroenterology
Date 2025 Jan 2
PMID 39744193
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neurocognitive impairment, including minimal hepatic encephalopathy (MHE) and overt hepatic encephalopathy, is one of the most common complications of all types of primary liver diseases, such as hepatitis B, biliary cholangitis, and autoimmune hepatitis. The EncephalApp Stroop test is a smartphone application-based test that is time-saving for MHE screening. However, neurocognitive impairment is different between alcoholic cirrhosis patients and nonalcoholic cirrhosis patients, so the cutoff value for MHE diagnosis might be inflated.

Aim: To validate the Stroop test in nonalcoholic cirrhosis patients.

Methods: This external validation was performed at the National Center for Infectious Diseases (Beijing). Liver cirrhosis patients aged between 18 and 65 years who voluntarily enrolled in the study and provided signed informed consent were included. The Psychometric Hepatic Encephalopathy Score (PHES) test was used as the standard diagnostic criterion for MHE. The EncephalApp Stroop test was then performed on the iPad, including two sessions of tests ("off" and "on") to measure patients' ability to differentiate between numbers and letters. We assessed the performance of the EncephalApp Stroop test in terms of the area under the curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value, with the PHES as the standard criterion.

Results: A total of 160 nonalcoholic cirrhosis patients were included in this validation study, including 87 (54.4%) patients without MHE and 73 (45.6%) patients with MHE. Taking the PHES as the gold standard, the EncephalApp Stroop test performed well for nonalcoholic liver cirrhosis patients in terms of "off" time [AUC: 0.85, 95% confidence interval (CI): 0.79-0.91] and "on + off" time (AUC: 0.85, 95%CI: 0.80-0.91); however, total runs of "off" session (AUC: 0.61, 95%CI: 0.52-0.69), total runs of "on" session (AUC: 0.57, 95%CI: 0.48-0.65), and "on - off" time (AUC: 0.54, 95%CI: 0.44-0.63) were comparatively low. The optimal cutoff points were "off" time > 101.93 seconds and "on + off" time > 205.86 seconds, with sensitivities of 0.84 and 0.90, specificities of 0.77 and 0.71, positive predictive values of 0.75 and 0.72, and false-positive values of 0.85 and 0.89, respectively.

Conclusion: Our results suggest that different cutoffs should be used for the EncephalApp Stroop tool for MHE screening between alcoholic and nonalcoholic living patients, which is a critical check before generalization to screen for neurocognitive impairment among the whole population of chronic liver diseases.

Citing Articles

Innovative diagnostic tool aids screening for minimal hepatic encephalopathy in non-alcoholic cirrhosis patients.

Li T, Li Y World J Hepatol. 2025; 17(1):101420.

PMID: 39871897 PMC: 11736476. DOI: 10.4254/wjh.v17.i1.101420.

References
1.
Subasinghe S, Nandamuni Y, Ranasinghe S, Niriella M, Miththinda J, Dassanayake A . Association between road accidents and low-grade hepatic encephalopathy among Sri Lankan drivers with cirrhosis: a prospective case control study. BMC Res Notes. 2016; 9:303. PMC: 4907045. DOI: 10.1186/s13104-016-2106-3. View

2.
Wang J, Bajaj J, Wang J, Shang J, Zhou X, Guo X . Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. J Dig Dis. 2019; 20(10):547-556. DOI: 10.1111/1751-2980.12816. View

3.
Tapper E, Parikh N, Waljee A, Volk M, Carlozzi N, Lok A . Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. Am J Gastroenterol. 2018; 113(4):529-538. DOI: 10.1038/ajg.2018.6. View

4.
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen K . Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715-35. DOI: 10.1002/hep.27210. View

5.
Shan C, Lee S, Chang Y, Wu J, Chen S, Chen S . Neuropsychological functions in Han Chinese patients in Taiwan with bipolar II disorder comorbid and not comorbid with alcohol abuse/alcohol dependence disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(1):131-6. DOI: 10.1016/j.pnpbp.2010.10.004. View